NCT00580658

Brief Summary

The purpose of this study is to allow patients to undergo deep brain stimulation (DBS) surgery for the treatment of dystonia. This is NOT a research study, but rather, a requirement by the FDA for humanitarian use of the deep brain stimulator device in the treatment of this rare disorder. Use of DBS for dystonia is approved for humanitarian use by the FDA in the treatment of chronic, intractable (drug refractory) dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years or older. Thus, this proposal request authorization by the IRB to allow patients at VUMC to access this HUD therapy.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 13, 2007

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 27, 2007

Completed
Last Updated

October 14, 2019

Status Verified

October 1, 2019

First QC Date

December 13, 2007

Last Update Submit

October 9, 2019

Conditions

Keywords

DystoniaDBS

Interventions

Activa Therapy, Gpi

Also known as: DBS, Gpi, Activa Therapy

Eligibility Criteria

Age7 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients whose ages are in the range of 7 and 99 years old
  • Patients who are diagnosed with chronic, intractable (drug refractory)primary dystonia, including generalized and or segmental dystonia, hemidystonia, and cervical dystonia (torticollis)as determined by a neurologist or neurosurgeon.
  • Patients who have failed appropriate medical therapy as determined by the SMD conference

You may not qualify if:

  • Patients younger than 7 years old
  • Patients who are at significant surgical risk as determined by the neurosurgeon and/or anesthesiologist.
  • Patients who have not had an adequate trial of medical or non-surgical therapy as determined by the SMD conference.
  • Patients not deemed good candidates by the SMD conference group.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Conditions

Dystonia

Condition Hierarchy (Ancestors)

DyskinesiasNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Peter E Konrad, MD, Ph.D.

    Vanderbilt University, Dept. Neurosurgery

    PRINCIPAL INVESTIGATOR
  • Dario Englot, MD PhD

    Vanderbilt University, Dept. Neurosurgery

    PRINCIPAL INVESTIGATOR
  • Thomas L Davis, MD

    Vanderbilt University, Dept. Neurology

    PRINCIPAL INVESTIGATOR
  • John Y Fang, MD

    Vanderbilt University, Dept. Neurology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
expanded access
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Director of Functional Neurosurgery

Study Record Dates

First Submitted

December 13, 2007

First Posted

December 27, 2007

Last Updated

October 14, 2019

Record last verified: 2019-10

Locations